Immunology

Roughly 1 in 10 people around the world are living with immune-mediated diseases, including atopic dermatitis or eczema, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), psoriatic disease (psoriasis and psoriatic arthritis), and a number of allo- and autoantibody diseases that fall into the rare, rheumatic and maternal fetal segments of disease. Among this population, only a fraction receive advanced therapies that effectively treat these conditions.

Driven by this unmet need, and guided by actionable science, we are inspired to change the course of such diseases by advancing and delivering transformational therapies.

Disease areas

Autoantibody diseases

April 16, 2025

Gastroenterology

April 16, 2025

Immunodermatology

April 16, 2025

Respiratory

April 16, 2025

Rheumatology

April 16, 2025

Innovation

Discovering and developing oral therapies against advanced targets

Progressing safe and effective treatment options in the convenience of a pill.
Pioneering combination advanced therapies

With single-agent drugs, many patients experience a plateau effect, but combination therapy has the potential to deliver even more.
Introducing new pathways to open the aperture to more immune diseases

We identify diseases driven by a common immune pathway, then pursue targeted novel medicines that can differentially modulate that pathway, addressing many diseases with a single therapy.